Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (1,898,000)	$ (4,180,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,063,000	908,000
Depreciation and amortization	684,000	792,000
Provision for excess and obsolete inventory	1,573,000	387,000
Provision for bad debt	13,000
Gain on sales of equipment	(717,000)
Loss on disposition of Tantaline		162,000
Impairment charge		111,000
Changes in operating assets and liabilities, net of effects of disposition of Tantaline and sales of equipment:
Accounts receivable	(256,000)	1,841,000
Contract assets	(622,000)	566,000
Inventories	646,000	(2,308,000)
Employee retention credit receivable		1,529,000	$ (1,500,000)
Other assets	(150,000)	(47,000)
Accounts payable	(524,000)	(154,000)
Accrued expenses	472,000	(679,000)
Contract liabilities	(1,773,000)	866,000
Net cash used in operating activities	(1,489,000)	(206,000)
Cash flows from investing activities:
Purchase of property and equipment	(106,000)	(418,000)
Net proceeds from sales of equipment	250,000	597,000
Net cash used in disposition of Tantaline		(312,000)
Net cash provided by (used in) investing activities	144,000	(133,000)
Cash flows from financing activities:
Payments of long-term debt	(82,000)	(77,000)
Proceeds from exercise of stock options		76,000
Net cash used in financing activities	(82,000)	(1,000)
Net decrease in cash and cash equivalents	(1,427,000)	(340,000)
Cash and cash equivalents at beginning of year	14,025,000	14,365,000
Cash and cash equivalents at end of year	12,598,000	14,025,000	$ 14,365,000
Supplemental disclosure of cash flow information:
Income taxes paid	3,000	8,000
Interest paid	19,000	24,000
Inventory transferred to property, plant and equipment	$ 110,000